Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
Decision brief
Answer first · skim in under a minute
Antibody-drug conjugates (ADCs) represent a novel class of therapeutics that selectively target tumor cells and deliver concentrated cytotoxic payloads, showing significant antitumor activity in lung cancer. This analysis covers the latest evidence, key targets, and strategic implications for BD teams, investors, and analysts.
Antibody-drug conjugates in lung cancer are no longer theoretical: FDA accelerated approvals for Enhertu in HER2-mutant NSCLC, Emrelis in high c-Met non-squamous disease, and Datroway in pretreated EGFR-mutated NSCLC show how payload delivery is carving biomarker-defined niches while leaving most of the NSCLC market still open.
Contents10 sections
Key Takeaways
- Emrelis (telisotuzumab vedotin-tllv) received accelerated FDA approval on May 14, 2025 for locally advanced or metastatic non-squamous NSCLC with high c-Met overexpression after prior systemic therapy.
- LUMINOSITY reported a 35% ORR and 7.2-month median DOR in the high c-Met EGFR wild-type cohort that supported Emrelis.
- Datroway (datopotamab deruxtecan-dlnk) gained accelerated approval on June 23, 2025 for EGFR-mutated NSCLC after EGFR-directed therapy and platinum chemotherapy.
- Enhertu remains the HER2-mutant NSCLC ADC option under accelerated approval for patients who received prior systemic therapy, with confirmation still required.
What are ADCs delivering in lung cancer right now?
Antibody-drug conjugates pair a tumor-directed antibody with a cytotoxic payload through a linker, aiming to concentrate chemotherapy inside antigen-expressing cells.
In NSCLC, which accounts for most lung cancer diagnoses, ADCs are advancing as biomarker-selected salvage and post-TKI options rather than as unselected chemotherapy replacements.
A 2024–2025 review summarizing ADC design and lung-cancer clinical experience is available via PMC12016829, covering targets including HER2, HER3, TROP2, MET, CEACAM5, and DLL3.
How does Emrelis change the MET-high NSCLC pathway?
On May 14, 2025, FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for adults with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression (≥50% of tumor cells with strong 3+ staining) who received prior systemic therapy.
According to the FDA Emrelis approval notice, efficacy came from LUMINOSITY (NCT03539536): ORR 35% (95% CI 24–46) and median DOR 7.2 months (95% CI 4.2–12) in 84 EGFR wild-type, high c-Met patients.
Recommended dosing is 1.9 mg/kg IV every 2 weeks (max 190 mg for patients ≥100 kg). FDA also approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic.
Where does Datroway fit after EGFR TKIs?
FDA's oncology accelerated-approval tracker lists Datroway (datopotamab deruxtecan-dlnk) with a June 23, 2025 accelerated approval for locally advanced or metastatic EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy.
The agency's ongoing cancer accelerated approvals table also records confirmatory commitment TROPION-LUNG15 with a November 30, 2029 completion target.
That EGFR-focused label is narrower than early broad NSCLC ambitions for TROP2 ADCs, reinforcing that histology and genotype still gate commercial uptake.
What role does Enhertu still play in HER2-mutant NSCLC?
DailyMed labeling for Enhertu (fam-trastuzumab deruxtecan-nxki) continues to list HER2-mutant unresectable or metastatic NSCLC after prior systemic therapy as an accelerated-approval indication contingent on confirmatory benefit.
See the Enhertu DailyMed label for the current HER2-mutant NSCLC indication language and ILD warnings that remain central to risk management.
For BD teams, Enhertu sets the HER2 bar; Emrelis opens a protein-overexpression MET niche; Datroway occupies post-EGFR / post-platinum space.
What should oncology BD and investors prioritize next?
Map companion-diagnostic readiness (HER2 mutation tests, MET IHC, EGFR history) before modeling share, because each ADC label fails without testing infrastructure.
Compare interstitial lung disease and mucositis signals across DXd payloads versus microtubule-inhibitor ADCs when building combination or sequencing strategies.
Watch confirmatory randomized trials that can convert accelerated approvals or force withdrawals if OS or PFS benefits do not hold.
What remains unproven?
Accelerated ORR/DOR packages do not prove overall survival superiority versus best available alternatives in each biomarker niche.
Broader TROP2, HER3, CEACAM5, and DLL3 programs remain largely investigational for lung cancer; citing them as near-term standards overstates the evidence.
Unselected NSCLC use of ADCs is not supported by the current FDA labels summarized here.
Related NovaPharma coverage
- EMA backs datopotamab deruxtecan lung cancer access
- EMA backs datopotamab deruxtecan in advanced lung cancer
- FDA Keytruda adjuvant NSCLC coverage
Frequently Asked Questions
Which ADCs are FDA-approved for biomarker-defined NSCLC?
Three ADCs have NSCLC labels tied to biomarkers: Enhertu for HER2 (ERBB2)-mutant disease after prior systemic therapy; Emrelis for high c-Met non-squamous NSCLC after prior therapy; and Datroway for EGFR-mutated NSCLC after EGFR-directed therapy and platinum chemotherapy.
What did LUMINOSITY show for Emrelis?
In LUMINOSITY (NCT03539536), 84 evaluable patients with EGFR wild-type, non-squamous NSCLC and high c-Met overexpression had a confirmed ORR of 35% (95% CI 24–46) and median duration of response of 7.2 months, per FDA's May 14, 2025 accelerated-approval summary.
Why do ADCs still look like the tip of the iceberg in lung cancer?
Approved ADCs cover narrow biomarker slices of NSCLC. Many additional targets (HER3, CEACAM5, DLL3, and broader TROP2 strategies) remain investigational, so the commercial and clinical expansion depends on confirmatory trials and toxicity management, especially interstitial lung disease.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…